Premium
Favorable outcome with doxorubicin‐based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large‐cell lymphoma
Author(s) -
Zhang XiMei,
Li YeXiong,
Wang WeiHu,
Jin Jing,
Wang ShuLian,
Liu YuePing,
Song YongWen,
Ren Hua,
Fang Hui,
Zhou LiQiang,
Chen Bo,
Qi ShuNan,
Liu QingFeng,
Lu NingNing,
Liu XinFan,
Yu ZiHao
Publication year - 2013
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12060
Subject(s) - medicine , chemotherapy , stage (stratigraphy) , doxorubicin , oncology , radiation therapy , lymphoma , anaplastic large cell lymphoma , biology , paleontology
The aim of this study was to analyze outcomes in adult patients with early stage systemic anaplastic large‐cell lymphoma (ALCL) treated with doxorubicin‐based chemotherapy and radiotherapy. Forty‐six adult patients with early stage systemic ALCL received chemotherapy followed by radiotherapy. All patients except two received chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or a CHOP‐like regimen. Twenty patients had stage I disease, and 26 patients had stage II disease. The 5‐yr overall survival (OS), progression‐free survival (PFS), and local control rates for all patients were 84.4%, 63.6%, and 90.8%, respectively. The 5‐yr OS and PFS rates were 95.0% and 77.4% for Ann Arbor stage I disease, and 75.1% and 51.7% for stage II disease, respectively. Lymph node involvement was the main pattern of disease progression or relapse for these patients. Adult patients with early stage systemic ALCL treated with doxorubicin‐based chemotherapy and radiotherapy had a favorable prognosis.